Biocon published its unaudited consolidated financial results for the quarter ended June 30, 2026, in the Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on August 07, 2026. The newspaper advertisements include a Quick Response (QR) code and a weblink to access the complete financial results for the period. This publication follows the Board of Directors' approval of the results on August 05, 2026.

The company reported a consolidated net profit of ₹141 crore for Q1FY27, a 355% increase from ₹31 crore in the corresponding period last year. Total income rose 9% to ₹4,391 crore, driven by a 17% growth in the Biopharma segment. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by statutory auditors under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

Key financial metrics for the quarter reflect broad-based improvement across revenue and profitability parameters:

Net profit before exceptional items stood at ₹145 crore, up 245% from ₹42 crore in Q1FY26. Exceptional items reduced profit before tax by ₹13 crore in Q1FY27, compared to ₹17 crore in Q1FY26.

Segment Analysis

The Biopharma segment contributed ₹3,615 crore, an increase of 17% year-on-year. Biosimilars revenue grew 16% to ₹2,855 crore, while Generics revenue surged 21% to ₹760 crore. This growth was fueled by momentum from recent product launches including Bosaya™ and Aukelso™ in the U.S., and Yesafili™. Conversely, the Services segment revenue declined 16% to ₹736 crore from ₹875 crore in Q1FY26.

Corporate Actions

On May 07, 2026, the Board recommended a final dividend of ₹0.50 per equity share of ₹5 face value. Bobby Parikh completed his term as an Independent Director on July 22, 2026, while Nicholas Haggar will complete his term after the 48th Annual General Meeting scheduled for August 6, 2026. Siddharth Mittal has taken charge as CEO & Managing Director of Syngene International Limited.

Biocon 's Q1FY27 financial results fell short of analyst expectations across multiple metrics, drawing a range of responses from major brokerages. Revenue grew 10% year-on-year, but the headline growth was largely attributed to currency tailwinds rather than underlying business momentum. Biosimilar constant-currency growth stood at only 5%, while EBITDA margin contracted to 25.5%, reflecting ongoing pricing pressure and heightened competition in key markets.

Brokerage Ratings and Target Prices

The quarter prompted divergent assessments from brokerages, with ratings ranging from Buy to Sell. The following table summarises the key positions:

Citi: Sell Rating at ₹360

Citi maintained its Sell rating on Biocon with a target price of ₹360, citing a quarter that missed expectations due to weaker research services and biosimilars performance. The brokerage noted that while revenue rose 10%, the growth was predominantly driven by currency benefits. Biosimilar constant-currency growth of only 5% and an EBITDA margin decline to 25.5% were highlighted as key concerns amid pricing pressure and competition.

Bernstein: Underperform at ₹326

Bernstein retained its Underperform rating with a target price of ₹326. The brokerage observed that Q1 revenue grew 10% and EBITDA grew 7%, but sales remained approximately 5% below estimates. Biosimilars revenue grew 16% year-on-year yet missed estimates by 6%. While Bernstein acknowledged that second-half improvement is expected, it noted this is likely insufficient to justify current valuations.

HSBC: Buy at ₹490

HSBC maintained the most constructive view, holding a Buy rating with a target price of ₹490. The brokerage noted that Q1 biosimilar sales were stable at approximately US$300mn, with stronger sales anticipated in the second half and beyond. HSBC identified successful execution of new biosimilar launches, profitability improvement, and cash-flow generation as key factors for the company's turnaround.

Jefferies: Hold at ₹410

Jefferies maintained a Hold rating with a target price of ₹410, describing Q1 as weak across all three divisions. The brokerage noted that management views the June quarter as the trough, with improvement expected in the second half of FY27 through biosimilar scale-up and higher generic utilisation. Jefferies cut its FY27–29 EBITDA estimates by 1–5% in response to the quarterly performance.

Key Q1FY27 Performance Highlights

• Revenue growth: 10% year-on-year, largely driven by currency benefits
• Biosimilar constant-currency growth: 5%
• Biosimilars YoY growth: 16% (per Bernstein), missing estimates by 6%
• Biosimilar sales: Stable at approximately US$300mn (per HSBC)
• EBITDA growth: 7% (per Bernstein)
• EBITDA margin: 25.5%, reflecting pricing pressure and competition
• Sales vs. estimates: Approximately 5% below analyst forecasts

The quarter's underperformance across research services and biosimilars, combined with margin compression, has led the majority of brokerages to maintain cautious stances. Management's characterisation of the June quarter as a trough and expectations of a second-half recovery remain central to the near-term investment thesis, though views on whether that recovery will be sufficient differ significantly across the street.